Skip to main content

Table 2 Patient outcomes and complications

From: Physiological predictors of survival during high-frequency oscillatory ventilation inadults with acute respiratory distress syndrome

Variable

 

Airleak

 

   Air Leak before HFOV

22/102 (21.6 %)

   Persistent air Leak during HFOV

5/22 (22.7 %)

   New air leak during HFOV

2/80 (2.5 %)

Co-treatment

(Some patients received more than one co-treatment)

 

   Nitric oxide

21/102 (20.6%)

   MARS

1/102 (0.98%)

   Steroids

19/102 (18.6%)

   Prone position

20/102 (19.6%)

   rhAPC

3/102 (2.9%)

   None

56/102 (54.9%)

Mortality

 

   Post HFOV

49/102 (48%)

   ICU discharge

62/102 (60.8%)

   30-day

57/102 (55.9%)

Cause of death at 30-days

 

   Withdrawal of treatment

22/57 (38.6%)

   >2 organ failure

20/57 (35.1%)

   Cardiac arrhythmia

6/57 (10.5%)

   Refractory hypoxia

4/57 (7%)

   Sepsis

3/57 (5.3%)

   Profound hypotension

2/57 (3.5%)

  1. HFOV, high-frequency oscillatory ventilation; MARS, Molecular AdsorbentsRecirculation System; rhAPC, recombinant human Activated Protein C (Drotrecoginalfa activated, Xigris).